PhRMA Statement on Intellectual Property

Washington, D.C. (February 16, 2010) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the Department of Justice Task Force on Intellectual Property:

Seven New Biopharmaceutical Research Companies Join PhRMA’s Mission to Advance Medical Innovation

Washington, D.C. (December 8, 2009) — As part of its efforts to expand awareness of the importance of medical progress in the United States, the Pharmaceutical Research and Manufacturers of America (PhRMA) is announcing today the addition of seven new member companies [view members].

New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS

Washington, D.C. (November 24, 2009) America’s pharmaceutical research and biotechnology companies are testing 97 medicines and vaccines to treat or prevent HIV/AIDS and related conditions, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA). December 1 marks the 21st anniversary of “World AIDS Day” – a global awareness campaign that originated at the 1988 World Summit of Ministers of Health on Programmes for AIDS Prevention.

Report Shows Buffalo Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases

Buffalo, NY (September 17, 2009) — Twenty-eight innovative medicines are being developed by biopharmaceutical research companies with facilities in Buffalo, according to a new report released today at the Hauptman Woodward Medical Research Institute. The medicines are awaiting approval by the U.S. Food and Drug Administration (FDA) or are in human clinical trials.

PhRMA Statement of Support for Introduction of the Customs Facilitation and Trade Enforcement Reauthorization Act of 2009

Washington, D.C. (August 7, 2009) — The Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement regarding PhRMA support for Senate introduction of the Customs Facilitation and Trade Enforcement Reauthorization Act of 2009 (CFTERA):

PhRMA Statement Regarding Benefits of U.S. Innovation

Washington, D.C. (August 25, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Ken Johnson issued the following statement today in response to ‘Global Drug Discovery: Europe Is Ahead,’ a paper published in the August 25th edition of Health Affairs:

PhRMA Statement Supporting House Vote on Biosimilars

Washington, D.C. (July 31, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the U.S. House Committee on Energy & Commerce’s endorsement of reasonable data protection:

“PhRMA, along with research universities, patients and healthcare providers, support the development of a responsible, abbreviated approval pathway for biosimilars.

PhRMA Applauds President Obama For Highlighting Importance of Innovation

Washington, D.C. (July 2, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin released the following statement regarding President Obama’s remarks about the importance of innovation:

PhRMA Encouraged by Decline in Cancer Death Rate

Washington, D.C. (May 27, 2009) –– Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement regarding the American Cancer Society’s (ACS) report on the continued decline in cancer death rates:

PhRMA Statement on Global Intellectual Property Agenda: 2009 Special 301 Report

Washington, D.C. (May 4, 2009) — Chris Singer, president of the International Section of the Pharmaceutical Research and Manufacturers of America, issued the following statement today on the U.S. Trade Representative’s (USTR) "Special 301" annual report to Congress, outlining the Administration’s global intellectual property agenda:

Pages

Subscribe to RSS - Innovation